Carteolol
From Wikipedia, the free encyclopedia
Carteolol
|
|
Systematic (IUPAC) name | |
5-[2-hydroxy-3- (tert-butylamino) propoxy]- 3,4-dihydro-1H-quinolin-2-one | |
Identifiers | |
CAS number | |
ATC code | C07 S01ED05 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C16H24N2O3 |
Mol. mass | 292.373 g/mol |
Pharmacokinetic data | |
Bioavailability | 85% |
Metabolism | hepatic, active with 8-hyrdocarteolol |
Half life | 6-8 hours |
Excretion | Renal (50-70%) |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status | |
Routes | oral |
Carteolol is a beta blocking agent
[edit] External links
- El-Kamel A, Al-Dosari H, Al-Jenoobi F. "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.". Drug Deliv 13 (1): 55–9. doi: . PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.". Cornea 24 (2): 213–20. doi: . PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.
|